Differenzialdiagnostik des neurodegenerativen Parkinson-Syndroms mit nuklearmedizinischen Verfahren

P. T. Meyer; S. Hellwig; F. Amtage

doi:10.1055/s-0032-1312637

Der Nuklearmediziner, Table of Contents

Der Nuklearmediziner 2012; 35(02): 109-123
DOI: 10.1055/s-0032-1312637

Neurodegenerative Erkrankungen

Differenzialdiagnostik des neurodegenerativen Parkinson-Syndroms mit nuklearmedizinischen Verfahren

Differential Diagnostics of Neurodegenerative Parkinsonian Syndromes with Nuclear Medicine Procedures

Authors

P. T. Meyer

¹Abteilung Nuklearmedizin, Universitätsklinikum Freiburg
S. Hellwig

²Abteilung für Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg
F. Amtage

³Abteilung Neurologie, Universitätsklinikum Freiburg

Abstract

Zusammenfassung

Die korrekte Differenzierung der atypischen Parkinson-Syndrome (APS; Multisystematrophie, MSA; progressive supranukleäre Blickparese, PSP; kortikobasale Degeneration, CBD) vom idiopathischen Parkinson-Syndrom (Morbus Parkinson, PD) ist von herausragender therapeutischer und prognostischer Bedeutung. In der vorliegenden Übersichtsarbeit werden die typischen Befunde, ihre neuropathologischen Korrelate und die diagnostische Wertigkeit der in der klinischen Routine eingesetzten nuklearmedizinischen Verfahren erörtert und kritisch bewertet. Nach aktuellem Kenntnisstand erlaubt die [¹⁸F]FDG-PET eine sehr genaue Trennung zwischen PD und APS und ist hierbei der [¹²³I]FP-CIT- und [¹²³I]IBZM-SPECT sowie [¹²³I]MIBG-Szintigrafie deutlich überlegen. Zudem ermöglicht die [¹⁸F]FDG-PET als einziges der vorgenannten Verfahren eine zuverlässige Differenzierung zwischen den APS-Subgruppen. Aktuelle Studien untersuchen zudem den möglichen Nutzen der [¹⁸F]FDG-PET für die Risikostratifizierung hinsichtlich Demenz bei PD-Patienten. Ist die [¹⁸F]FDG-PET nicht verfügbar, bietet sich nach Meinung der Autoren vorrangig die [¹²³I]IBZM-SPECT oder die SPECT der regionalen zerebralen Perfusion an, wobei der diagnostische Nutzen der letzteren bisher nur unzureichend untersucht wurde.

Abstract

Correct differentiation between atypical parkinsonian syndromes (APS; multiple system atrophy, MSA; progressive supranuclear palsy, PSP; corticobasal degeneration, CBD) from idiopathic Parkinson’s disease (PD) is of paramount therapeutic and prognostic importance. In the present review article typical imaging findings, their neuropathological correlates and the diagnostic values of routinely used nuclear medicine procedures are discussed and critically evaluated. According to current knowledge, [¹⁸F]FDG-PET provides a very high diagnostic accuracy in differentiating PD and APS, which is clearly superior to the accuracy of [¹²³I]FP-CIT- or [¹²³I]IBZM-SPECT and [¹²³I]MIBG szintigraphy. Furthermore, [¹⁸F]FDG-PET is the only of the aforementioned techniques that allows for a reliable differentiation also between APS sub-groups. Current studies investigate the possible value of [¹⁸F]FDG-PET for risk stratification for dementia in PD. If [¹⁸F]FDG-PET is not available, in the authors’ opinion [¹²³I]IBZM-SPECT or SPECT imaging of regional cerebral perfusion should be preferred instead, although the diagnostic value of perfusion SPECT has not been properly validated so far.

Schlüsselwörter

Parkinson-Syndrom - SPECT - PET - Dopaminrezeptor - Dopamintransporter - zerebraler Glukosemetabolismus

Key words

Parkinsonian syndrome - SPECT - PET - dopamine receptor - dopamine transporter - cerebral glucose metabolism

Full Text

References

Literatur
1 Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol 2010; 20: 633-639
2 Antonini A, Benti R, De Notaris R et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003; 24: 149-150
3 Antonini A, Leenders KL, Vontobel P et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain 1997; 120: 2187-2195
4 Antonini A, Schwarz J, Oertel WH et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997; 12: 33-38
5 Bohnen NI, Koeppe RA, Minoshima S et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848-855
6 Bosman T, Van Laere K, Santens P. Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson’s disease. Eur J Nucl Med Mol Imaging 2003; 30: 16-24
7 Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 11: 351-355
8 Brooks DJ, Ibanez V, Sawle GV et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-192
9 Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med 2010; 51: 596-609
10 Dickson DW, Braak H, Duda JE et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157
11 Eckert T, Barnes A, Dhawan V et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26: 912-921
12 Eckert T, Van Laere K, Tang C et al. Quantification of Parkinson’s disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007; 34: 496-501
13 Eidelberg D, Dhawan V, Moeller JR et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991; 54: 856-862
14 Eidelberg D, Moeller JR, Dhawan V et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14: 783-801
15 Eidelberg D, Takikawa S, Moeller JR et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease. Ann Neurol 1993; 33: 518-527
16 El Fakhri G, Habert MO, Maksud P et al. Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2006; 33: 87-92
17 Filippi L, Manni C, Pierantozzi M et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson’s disease: a SPECT semiquantitative study. Nucl Med Commun 2006; 27: 381-386
18 Foster NL, Gilman S, Berent S et al. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988; 24: 399-406
19 Garraux G, Salmon E, Degueldre C et al. Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage 1999; 10: 149-162
20 Garraux G, Salmon E, Peigneux P et al. Voxel-based distribution of metabolic impairment in corticobasal degeneration. Mov Disord 2000; 15: 894-904
21 Goldstein DS. Functional neuroimaging of sympathetic innervation of the heart. Ann N Y Acad Sci 2004; 1018: 231-243
22 Hellwig S, Amtage F, Kreft A et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology (in press)
23 Hierholzer J, Cordes M, Venz S et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med 1998; 39: 954-960
24 Hosaka K, Ishii K, Sakamoto S et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 2002; 199: 67-71
25 Hu MT, Taylor-Robinson SD, Chaudhuri KR et al. Cortical dysfunction in non-demented Parkinson’s disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000; 123: 340-352
26 Ishibashi K, Saito Y, Murayama S et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 2010; 37: 3-11
27 Jokinen P, Scheinin N, Aalto S et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia. Parkinsonism Relat Disord 2010; 16: 666-670
28 Juh R, Kim J, Moon D et al. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004; 51: 223-233
29 Juh R, Pae CU, Kim TS et al. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005; 383: 22-27
30 Kahraman D, Eggers C, Schicha H. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson’s disease. J Neurol 2012; 259: 251-260
31 Kempster PA, Williams DR, Selikhova M et al. Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 2007; 130: 2123-2128
32 Kim YJ, Ichise M, Ballinger JR et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17: 303-312
33 Klaffke S, Kuhn AA, Plotkin M et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006; 21: 1724-1727
34 Knudsen GM, Karlsborg M, Thomsen G. Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004; 31: 1631-1638
35 Koch W, Hamann C, Radau PE et al. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?. Eur J Nucl Med Mol Imaging 2007; 34: 1265-1273
36 Kouri N, Whitwell JL, Josephs KA et al. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7: 263-272
37 Kuhl DE, Metter EJ, Riege WH et al. Patterns of cerebral glucose utilization in Parkinson’s disease and Huntington’s disease. Ann Neurol 1984; (15 Suppl) S119-S125
38 Kurata T, Kametaka S, Ohta Y et al. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage. Intern Med 2011; 50: 2775-2781
39 la Fougère C, Pöpperl G, Levin J et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 2010; 51: 581-587
40 Lin WY, Lin KJ, Weng YH et al. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy. Nucl Med Commun 2010; 31: 974-980
41 Ling H, O’Sullivan SS, Holton JL et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133: 2045-2057
42 Lippa CF, Duda JE, Grossman M et al. DLB/PDD Working Group . DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819
43 Litvan I, Goetz CG, Jankovic J et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997; 54: 937-944
44 Litvan I, MacIntyre A, Goetz CG et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55: 969-978
45 Lu CS, Weng YH, Chen MC et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 2004; 45: 49-55
46 Lyoo CH, Jeong Y, Ryu YH et al. Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol 2010; 64: 65-73
47 Lyoo CH, Jeong Y, Ryu YH et al. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain 2008; 131: 438-446
48 McKeith I. Dementia with Lewy bodies and Parkinson’s disease with dementia: where two worlds collide. Pract Neurol 2007; 7: 374-382
49 Messa C, Volonté MA, Fazio F et al. Differential distribution of striatal [123I]beta-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 1998; 25: 1270-1276
50 Meyer PT, Sattler B, Winz OH et al. Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach. Neuroimage 2008; 42: 548-558
51 Meyer PT, Winz OH, Dafotakis M et al. Improved visual [(123)I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. Q J Nucl Med Mol Imaging 2011; 55: 301-309
52 Minoshima S, Frey KA, Koeppe RA et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-1248
53 Mo SJ, Linder J, Forsgren L et al. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study. Eur J Nucl Med Mol Imaging 2010; 37: 2154-2164
54 Nagahama Y, Fukuyama H, Turjanski N et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997; 12: 691-696
55 Nagayama H, Hamamoto M, Ueda M et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005; 76: 249-251
56 Nagayama H, Ueda M, Yamazaki M et al. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010; 25: 1744-1747
57 Nakagawa M, Kuwabara Y, Taniwaki T et al. PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. Ann Nucl Med 2005; 19: 267-275
58 Osaki Y, Ben-Shlomo Y, Lees AJ et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004; 19: 181-189
59 Osaki Y, Wenning GK, Daniel SE et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy?. Neurology 2002; 59: 1486-1491
60 O’Sullivan SS, Massey LA, Williams DR et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131: 1362-1372
61 Otsuka M, Kuwabara Y, Ichiya Y et al. Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with 18F-dopa and 18F-FDG. Ann Nucl Med 1997; 11: 251-257
62 Park HK, Kim JS, Im KC et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses. Mov Disord 2009; 24: 237-245
63 Peppard RF, Martin WR, Carr GD et al. Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol 1992; 49: 1262-1268
64 Perani D, Bressi S, Testa D et al. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study. Arch Neurol 1995; 52: 179-185
65 Piert M, Koeppe RA, Giordani B et al. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson’s disease. J Nucl Med 1996; 37: 1115-1122
66 Pirker W, Asenbaum S, Bencsits G. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000; 15: 1158-1167
67 Plotkin M, Amthauer H, Klaffke S. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112: 677-692
68 Raffel DM, Koeppe RA, Little R et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 2006; 47: 1769-1777
69 Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-758
70 Schreckenberger M, Hägele S, Siessmeier T et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2004; 31: 1128-1135
71 Schwarz J, Tatsch K, Arnold G et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993; 43 (Suppl. 06) S17-S20
72 Schwarz J, Tatsch K, Gasser T et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13: 16-19
73 Sone M, Yoshida M, Hashizume Y et al. alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol 2005; 110: 19-26
74 Spiegel J, Möllers MO, Jost WH et al. FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov Disord 2005; 20: 552-561
75 Srulijes K, Reimold M, Liscic RM et al. Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism. Mov Disord 2012; 27: 151-155
76 Südmeyer M, Antke C, Zizek T. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med 2011; 52: 733-740
77 Tang CC, Poston KL, Eckert T et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9: 149-158
78 Tatsch K, Schwarz J, Oertel WH et al. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 1991; 12: 699-707
79 Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol 2006; 5: 75-86
80 Treglia G, Stefanelli A, Cason E et al. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson’s disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg 2011; 113: 823-829
81 Van Laere K, Casteels C, De Ceuninck L et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med 2006; 47: 384-392
82 Vander Borght T, Minoshima S, Giordani B et al. Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med 1997; 38: 797-802
83 Verstappen CC, Bloem BR, Haaxma CA et al. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson’s disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2007; 34: 502-507
84 Vlaar AM, de Nijs T, Kessels AG et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59: 258-266
85 Vlaar AM, van Kroonenburgh MJ, Kessels AG et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7: 27
86 Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007; 13 (Suppl. 03) S336-S340
87 Wenning GK, Colosimo C, Geser F et al. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103
88 Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270-279
89 Yong SW, Yoon JK, An YS et al. A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol 2007; 14: 1357-1362